# Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma

> **NCT05918094** · PHASE3 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 540 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Experimental dose: modified XELOX + sintilimab
- **DRUG:** Standard dose: standard XELOX + sintilimab

## Key facts

- **NCT ID:** NCT05918094
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-30
- **Primary completion:** 2026-12
- **Final completion:** 2028-12
- **Target enrollment:** 540 (ESTIMATED)
- **Last updated:** 2024-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05918094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05918094, "Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05918094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*